268 related articles for article (PubMed ID: 31542806)
1. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
Morrissey KM; Marchand M; Patel H; Zhang R; Wu B; Phyllis Chan H; Mecke A; Girish S; Jin JY; Winter HR; Bruno R
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1257-1267. PubMed ID: 31542806
[TBL] [Abstract][Full Text] [Related]
2. Model-based simulation to support the extended dosing regimens of atezolizumab.
Chou CH; Hsu LF
Eur J Clin Pharmacol; 2021 Jan; 77(1):87-93. PubMed ID: 32808071
[TBL] [Abstract][Full Text] [Related]
3. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.
Lala M; Li TR; de Alwis DP; Sinha V; Mayawala K; Yamamoto N; Siu LL; Chartash E; Aboshady H; Jain L
Eur J Cancer; 2020 May; 131():68-75. PubMed ID: 32305010
[TBL] [Abstract][Full Text] [Related]
4. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.
Long GV; Tykodi SS; Schneider JG; Garbe C; Gravis G; Rashford M; Agrawal S; Grigoryeva E; Bello A; Roy A; Rollin L; Zhao X
Ann Oncol; 2018 Nov; 29(11):2208-2213. PubMed ID: 30215677
[TBL] [Abstract][Full Text] [Related]
5. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.
Bi Y; Liu J; Furmanski B; Zhao H; Yu J; Osgood C; Ward A; Keegan P; Booth BP; Rahman A; Wang Y
Ann Oncol; 2019 Apr; 30(4):644-651. PubMed ID: 30715147
[TBL] [Abstract][Full Text] [Related]
6. Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation.
Liu SN; Marchand M; Liu X; Ingle G; Maiya V; Graupner V; Elze MC; Chan P; Hsu JC; Lin A; Vadhavkar S; Wu B; Bruno R
J Clin Pharmacol; 2022 Nov; 62(11):1393-1402. PubMed ID: 35576521
[TBL] [Abstract][Full Text] [Related]
7. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Rittmeyer A; Barlesi F; Waterkamp D; Park K; Ciardiello F; von Pawel J; Gadgeel SM; Hida T; Kowalski DM; Dols MC; Cortinovis DL; Leach J; Polikoff J; Barrios C; Kabbinavar F; Frontera OA; De Marinis F; Turna H; Lee JS; Ballinger M; Kowanetz M; He P; Chen DS; Sandler A; Gandara DR;
Lancet; 2017 Jan; 389(10066):255-265. PubMed ID: 27979383
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of dosing strategy for pembrolizumab for oncology indications.
Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
[TBL] [Abstract][Full Text] [Related]
10. In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation.
Peer CJ; Schmidt KT; Arisa O; Richardson WJ; Paydary K; Goldstein DA; Gulley JL; Figg WD; Ratain MJ
J Clin Pharmacol; 2023 Jun; 63(6):672-680. PubMed ID: 36624662
[TBL] [Abstract][Full Text] [Related]
11. Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types.
Zhao X; Shen J; Ivaturi V; Gopalakrishnan M; Feng Y; Schmidt BJ; Statkevich P; Goodman V; Gobburu J; Bello A; Roy A; Agrawal S
Ann Oncol; 2020 Feb; 31(2):302-309. PubMed ID: 31959348
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
Hui R; Garon EB; Goldman JW; Leighl NB; Hellmann MD; Patnaik A; Gandhi L; Eder JP; Ahn MJ; Horn L; Felip E; Carcereny E; Rangwala R; Lubiniecki GM; Zhang J; Emancipator K; Roach C; Rizvi NA
Ann Oncol; 2017 Apr; 28(4):874-881. PubMed ID: 28168303
[TBL] [Abstract][Full Text] [Related]
13. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
[TBL] [Abstract][Full Text] [Related]
14. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
Chatterjee M; Turner DC; Felip E; Lena H; Cappuzzo F; Horn L; Garon EB; Hui R; Arkenau HT; Gubens MA; Hellmann MD; Dong D; Li C; Mayawala K; Freshwater T; Ahamadi M; Stone J; Lubiniecki GM; Zhang J; Im E; De Alwis DP; Kondic AG; Fløtten Ø
Ann Oncol; 2016 Jul; 27(7):1291-8. PubMed ID: 27117531
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Powles T; Durán I; van der Heijden MS; Loriot Y; Vogelzang NJ; De Giorgi U; Oudard S; Retz MM; Castellano D; Bamias A; Fléchon A; Gravis G; Hussain S; Takano T; Leng N; Kadel EE; Banchereau R; Hegde PS; Mariathasan S; Cui N; Shen X; Derleth CL; Green MC; Ravaud A
Lancet; 2018 Feb; 391(10122):748-757. PubMed ID: 29268948
[TBL] [Abstract][Full Text] [Related]
16. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
Powderly J; Spira A; Kondo S; Doi T; Luke JJ; Rasco D; Gao B; Tanner M; Cassier PA; Gazzah A; Italiano A; Tosi D; Afar DE; Parikh A; Engelhardt B; Englert S; Lambert SL; Kasichayanula S; Mensing S; Menon R; Vosganian G; Tolcher A
Clin Transl Sci; 2021 Jan; 14(1):277-287. PubMed ID: 32770720
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P).
Langley RG; Papp K; Gooderham M; Zhang L; Mallinckrodt C; Agada N; Blauvelt A; Foley P; Polzer P;
Br J Dermatol; 2018 Jun; 178(6):1315-1323. PubMed ID: 29405255
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.
von Pawel J; Bordoni R; Satouchi M; Fehrenbacher L; Cobo M; Han JY; Hida T; Moro-Sibilot D; Conkling P; Gandara DR; Rittmeyer A; Gandhi M; Yu W; Matheny C; Patel H; Sandler A; Ballinger M; Kowanetz M; Park K
Eur J Cancer; 2019 Jan; 107():124-132. PubMed ID: 30562710
[TBL] [Abstract][Full Text] [Related]
19. Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma.
Novakovic AM; Wilkins JJ; Dai H; Wade JR; Neuteboom B; Brar S; Bello CL; Girard P; Khandelwal A
Clin Pharmacol Ther; 2020 Mar; 107(3):588-596. PubMed ID: 31553054
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).
Garralda E; Oh DY; Italiano A; Bedard PL; Delord JP; Calvo E; LoRusso P; Wainberg Z; Cervantes A; Rodriguez-Vida A; Shemesh CS; Sane R; Mendus D; Ding H; Hendricks R; Meng R; Cho BC; Kim TW; Wu B
J Clin Pharmacol; 2024 May; 64(5):544-554. PubMed ID: 38105505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
